Fingerprint
Dive into the research topics of 'A phase II open label clinical study of the safety, tolerability and efficacy of ILB® for amyotrophic lateral sclerosis'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
A phase II open label clinical study of the safety, tolerability and efficacy of ILB® for amyotrophic lateral sclerosis
Ann Logan, Zsuzsanna Nagy, Nicholas Barnes, Tony Belli, Valentina Di Pietro, Barbara Tavazzi, Giuseppe Lazzarino, Giacomo Lazzarino, Lars Bruce, Lennart I. Persson
Research output: Contribution to journal › Article › peer-review
49
Downloads
(Pure)